References
- Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;11.DOI: 10.1155/2011/562790
- Elias A, Ijeoma O, Edikpo NJ, et al. Evaluation of cohorts and clinical studies-part one. Pharmacol Pharm. 2013;4:651–662.
- Scarpino M, Pinzone MR, Di Rosay M, et al. Kidney disease in HIV-infected patients. Eur Rev Med Pharmacol Sci. 2013;17:2660–2667.
- Baxi SM, Scherzer R, Greenblatt RM, et al. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS. 2016;30(4):609–618.
- Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011. DOI: 10.1155/2011/354908
- National Department of Health Republic of South Africa. South African antiretroviral treatment clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. Published May 2019.
- Hall AM. Update on tenofovir toxicity in the kidney. Pediatric Nephrol. 2013;28:1011–1023.
- The standard treatment guidelines and essential medicines list for South Africa. © Department of Health, Republic of South Africa December 2014.
- World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommended for a public health approach 2nd edition. 2016.
- Jose S, Hamzan L, Campbell LJ, et al. Incomplete reversibility of estimated glomerular filtration rate decline following disoproxil fumarate exposure. J Infect Dis. 2014;210(3):363–373.
- Venter W, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19(1):817.
- Chadwick DR, Sarfo FS, Kirk ESM, et al. Tenofovir is associated with increased proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol. 2015;16 (1)(195).
- Patel KK, Patel AK, Ranjan RR, et al. Tenofovir-associated renal dysfunction in clinical practice: observational cohort from western India. Indian J Sex Transm Dis AIDS. 2010;31(1):30–34.
- Kamkuemah M, Kaplan R, Bekker LG, et al. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a primary healthcare setting in South Africa. Trop Med Int Health. 2014;20(4):518–526.
- Li X, Zhuang S. Acute kidney injury in HIV infection. J Trop Diseases. 2013;1:101.
- Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171–1177.
- Bonjoch A, Echeverria P, Perez-Alvarez N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Elsevier. 2012;96(1):65–69.
- Yoshino M, Yagura H, Kushida H, et al. Assessing recovery of renal function after disoproxil fumarate discontinuation. J Infect Chemother. 2012;18(2):169–174.
- Wever K, van Agtmael M, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55(1):78–81.
- De Boer Y, De Lannoy R, Orhan R, et al. Reversibility of tenofovir nephrotoxicity in HIV-positive patients: a systemic review. Erasmus J Med. 2015;5(1) p.38.
- Sandre A, Mushi N, Dhande S, et al. Tenofovir-induced acute kidney injury in HIV-infected patients in western India: a resource limited setting perspective. Int AIDs Soc. 2012;15:18308.
- Gupta A, Wood R, Kaplan R, et al. Prevalent and Incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS ONE. 2013;8(2):e55824.
- Levin A, Stevens PE. Summary of KDIGO 2012 guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1): 49–6.
- Statistics South Africa: mid-year population estimates. 2018. [cited 2020 Apr 20]. Available from: www.statsa.gov.za
- Shisana O, Rice K, Zungu N, et al. Gender and poverty in South Africa in the era of HIV/AIDs: A quantitative study. J Women’s Health. 2010;19(1). DOI:10.1089/jwh.2008.1200.
- Franey C, Knott D, Barnighausen T, et al. Renal impairment in rural African antiretroviral programme. BMC Infect Dis. 2009;9:143.
- Ojeh BV, Abah IO, Ugoagwu P, et al. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients. Germs. 2018;8(2):67–76.
- Vance DE, Mugavero M, Raper JL, et al. Aging with HIV: A cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2011;22(1):17–19.
- Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875.
- Ibrahim F, Naftalin C, Cheserem E, et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. Clin Sci. 2010;24(14):2239–2244.
- Kyaw NT, Harries CP, Antierens A, et al. Low incidence of renal dysfunction among HIV-infected patients on a tenofovir based first line antiretroviral treatment regimen in Myanmar. Plos One. 2015;10(8):e0135188.
- Boswell MT, Rossouw TM. Approach to acute kidney injury in HIV-infected patients in South Africa. South Afr J HIV Med. 2017;18(1):714.
- Choto M, Chitura M. Factors associated with antiretroviral treatment default at citimed hospital, Zimbabwe. Afr Educat Res J. 2017;5(4): 215–220. ISSN: 2354-2160.
- Amond A, Motala A, Levitt N, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes. J Endocrinol Metabolism Diabetes South Afr. 2012;17(1):S1–S94.
- Supran HS, Gokhale S, Sathian B, et al. Hepatitis B virus (HBV and Hepatitis C virus (HCV) co-infection among HIV individuals at Tertiary care hospital in western Nepal. Nepal J Epidemiol. 2015;5(2):488–493.
- Rouet F, Deleplancque I, Mboumba BB, et al. Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV positive adults from Gabon (Central Africa). Plos One. 2015;10(1):e0116975.
- Matthews C, Beloukas A, Malik A, et al. Prevalence and characteristics of hepatitis B virus (HBV) co-infection among HIV positive women in South Africa and Botswana. Plos One. 2015;10(7):e0134037.
- Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. In: Uetrech J, editor. adverse drug reactions. Handbook of experimental pharmacology. Vol. 196, 2010:111-130. Springer, Berlin,Heildelberg.
- Zitha AN, Schellack N, Gous AGS. Renal monitoring of patients treated with tenofovir at Odi hospital in Gauteng province, South Africa. Afr J Phys Health Sci (AJPHES). 2017;1:128–145.
- Chua AC, Llorin RM, Lai K, et al. Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort. AIDS Res Ther. 2012;9(1).:19
- De Waal R, Cohen K, Fox M, et al. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: A retrospective cohort study. J Int AIDS Soc. 2017;20:21317.
- De Beaudrap P, Diallo MB, Landman R, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses. 2010;26(11). DOI:10.1089/aid.2009.0261.
- Munikrishnappa D. Chapter 6: limitations of various formulae and other ways of assessing GFR in the elderly: is there a role for cystatin C.. Am Soc Nephrol. 2009.